# การวิเคราะห์ต้นทุน-ประสิทธิผลของศูนย์บำบัดรักษาวัณโรค ของภาครัฐและรัฐร่วมเอกชนในเนปาล : กรณีศึกษากรุงกาฐมัณฑุ



นายเดเวนดรา ปราสาท กนาวาลี

วิทยานิพนธ์นี้เป็นส่วนหนึ่งของการศึกษาตามหลักสูตรปริญญาวิทยาศาสตรมหาบัณฑิต สาขาวิชาเศรษฐศาสตร์สาธารณสุข คณะเศรษฐศาสตร์ จุฬาลงการณ์มหาวิทยาลัย ปีการศึกษา 2544 ISBN: 974-17-0825-4 ลิขสิทธิ์ของจุฬาลงกรณ์มหาวิทยาลัย

# COST-EFFECTIVENESS ANALYSIS OF PUBLIC AND PUBLIC-PRIVATE MIX DOTS TREATMENT CENTERS IN NEPAL: A CASE STUDY OF KATHMANDU METROPOLITAN CITY

Mr. Devendra Prasad Gnawali

A Thesis Submitted in Partial Fulfillment of the Requirements

For the Degree of Master of Science in Health Economics

Faculty of Economics

Chulalongkorn University

Academic Year 2001

ISBN: 974-17-0825-4

© Copyright of Chulalongkorn University

Thesis Title	: COST-EFFECTIVENESS ANALYSIS OF PUBLIC
	AND PUBLIC-PRIVATE MIX DOTS TREATMENT
	CENTERS IN NEPAL: A CASE STUDY OF
	KATHMANDU METROPOLITAN CITY
Ву	: Devendra Prasad Gnawali
Field of Study	: Health Economics
Thesis Advisor	: Associate Professor Isra Sarntisart, Ph.D.
Accepted by	y the Faculty of Economics, Chulalongkorn University in Partial
	Requirements for Master's Degree
	and the state of t
	S.A.A. C.A.Dean, Faculty of Economics
	(Associate Professor Suthiphand Chirathivat, Ph.D.)
	(1850etate 1101essor Sutinpliand Chiradiivat, 111.D.)
THESIS COMMITT	TEE:
	Chairperson
	(Associate Professor Siripen Supakankunti, Ph.D)
	(13500iate 11010550i Biripeli Bupakalikuliti, 111.D)
	(Associate Professor Isra Sarntisart, Ph.D)
	P. KangMember
	(Professor Pirom Kamolratanakul, M.D, M.Sc.)
	`,,,

Foryn Member

(Associate Professor Pongsa Pornchaiwiseskul, Ph.D)

เดเวนตรา ปราสาท กนาวาลี : การวิเคราะห์ดันทุน-ประสิทธิผลของศูนย์บำบัดรักษาวัณโรคของ ภาครัฐและรัฐร่วมเอกชนในเนปาล : กรณีศึกษากรุงกาฐมัณฑุ. (COST-EFFECTIVENESS ANALYSIS OF PUBLIC AND PUBLIC-PRIVATE MIX DOTS TREATMENT CENTERS IN NEPAL: A CASE STUDY OF KATHMANDU METROPOLITAN CITY) อ.ที่ปรึกษา : รศ. ดร.อิศรา ศานติศาสน์, 122 หน้า. ISBN: 974-17-0825-4

วัณโรคเป็นปัญหาสุขภาพที่สำคัญปัญหาหนึ่งของเนปาล ประชากรร้อยละ 45 ดิดเชื้อวัณโรค โดยร้อยละ 60 เป็นกลุ่มอายุที่มีผลิตภาพทางเศรษฐกิจสูง ผู้ป่วยจำนวนมากเข้ารับการรักษาในสถาน-พยาบาลของเอกชน ตั้งแต่ปี พ.ศ. 2540 เนปาลได้ใช้แนวคิดของการบำบัดรักษารัฐร่วมเอกชน (PPM) ในการควบคุมวัณโรคภายใต้กลยุทธการรักษาแบบมีผู้สังเกตโดยตรง (DOTS)

วิทยานิพนธ์นี้ได้ทำการวิเคราะห์ต้นทุน-ประสิทธิผลของศูนย์บำบัดรักษาในมุมมองของผู้ให้-บริการ ศูนย์บำบัดรักษาภาครัฐ 2 แห่ง และศูนย์บำบัดรักษารัฐร่วมเอกชน 2 แห่ง ถูกเลือกเป็นตัวอย่าง ในการศึกษา ข้อมูลที่ใช้เป็นข้อมูลในช่วง 8 เดือนแรกของปีงบประมาณ 2543/44 ข้อมูลต้นทุนผู้ให้บริการ และผลการรักษาได้จากศูนย์บำบัดรักษาทั้ง 4 แห่ง ข้อมูลค่ายา ค่าวัสดุและอุปกรณ์การแพทย์ได้จากศูนย์ บริการวัณโรคแห่งชาติ

ต้นทุนเฉลี่ยต่อประสิทธิผลของศูนย์บำบัดรักษาภาครัฐ มีค่าประมาณ 110.6 เหรียญสหรัฐฯ สูงกว่าต้นทุนของศูนย์บำบัดรักษารัฐร่วมเอกชนซึ่งมีค่า 47.4 เหรียญสหรัฐฯ ผลจากการศึกษาชี้ว่าต้นทุน ด้านสินค้าทุนของศูนย์บำบัดรักษาทุกแห่งมีสัดส่วนไม่เกินร้อยละ 9.7 ในขณะที่ดันทุนด้านแรงงาน แตกต่างกันดั้งแต่ร้อยละ 17 ถึง ร้อยละ 49 ผลการศึกษาชี้ให้เห็นว่าการบำบัดรักษาของศูนย์บำบัดรักษา รัฐร่วมเอกชนมีประสิทธิผลใกล้เคียงหรือสูงกว่ามาตรฐานขององค์การอนามัยโลก (WHO) และศูนย์วัณโรค แห่งชาติ (NTC) ในขณะที่การบำบัดรักษาของศูนย์บำบัดรักษาภาครัฐมีประสิทธิผลต่ำกว่ามาตรฐาน โดยสรุปแล้วอาจกล่าวได้ว่า ศูนย์บำบัดรักษารัฐร่วมเอกชนน่าจะมีต้นทุนต่อประสิทธิผลที่ดีกว่าศูนย์บำบัดรักษาภาครัฐ ทั้งในด้านการลดการป่วยและการตายจากวัณโรคในเขตเทศบาลซึ่งเป็นไปตามวัตถุประสงค์ ของประเทศ ผลการศึกษานี้ยังชี้ให้เห็นถึงความจำเป็นที่จะต้องส่งเสริมการดำเนินการศูนย์บำบัดรักษารัฐร่วมเอกชนในเขตเมืองของเนปาลให้มากยิ่งขึ้นต่อไป

ภาควิชา เศรษฐศาสตร์ สาขาวิชา เศรษฐศาสตร์สาธารณสุข ปีการศึกษา 2544

# 4485803129: MAJOR HEALTH ECONOMICS

KEYWORDS: TUBERCULOSIS/ DOTS TREATMENT /COST-EFFECTIVENESS/ PUBLIC-PRIVATE MIX/ KATHMANDU/ NEPAL

DEVENDRA PRASAD GNAWALI: COST-EFFECTIVENESS ANALYSIS OF PUBLIC AND PUBLIC-PRIVATE MIX DOTS TREATMENT CENTERS IN NEPAL: A CASE STUDY OF KATHMANDU METROPOLITAN CITY. THESIS ADVISOR: ASSOC. PROF. ISRA SARNTISART, Ph.D., 122 pp. ISBN: 974-17-0825-4

Tuberculosis is one of the major public health problems in Nepal. About 45% of the population is infected with TB, out of which 60% are in economically active age group. A substantial number of TB cases (about 40-50%) are being treated by private sector. To manage this bulk of active TB patients properly, PPM-DOTS service seems to be more important. Since 1997, Nepal has been practicing public-private mix concept in tuberculosis control, basically after implementation of Directly Observed Treatment, Short Course (DOTS) strategy.

This cost-effectiveness analysis was carried out in Kathmandu Metropolitan City from provider perspective. Two public and two public-private mix DOTS centers were selected for the study purpose. The evaluation period was first eight months of F/Y 2000/01. Data on providers' costs were collected from DOTS centers. Drug cost/ laboratory reagent cost/equipment cost were obtained from National Tuberculosis Center. Treatment outcomes were collected from DOTS centers.

The average cost per effectiveness in public DOTS centers was about US\$ 110.6, while that was US\$ 47.4 in PPM-DOTS centers. The results also show that capital cost of each DOTS center did not exceed more than 9.7% of total provider cost. But labor costs varied from 17-49%. In public DOTS centers the range of labor cost was 30-48%, while in PPM-DOTS centers it was 17-24% of total provider cost. The observed treatment outcome in PPM-DOTS centers seems to be effective. It was either approaching or better than the standard set by WHO/NTC, while that of public DOTS centers was far below from the target. In conclusion, PPM DOTS centers seem to be more costeffective than public DOTS centers. In urban area, PPM-DOTS centers could help reduce tuberculosis related morbidity and mortality and hence to achieve National Tuberculosis Center's (NTC) objectives. NTC could increase the efficiency of its activities with private providers. Thus, this study could suggest the wider implementation of PPM-DOTS service for tuberculosis in urban area of Nepal.

Department Economics Student's Signature.

Field of Study Health Economics Advisor's Signature

Academic Year 2001

#### Acknowledgements

I would like to express my sincere gratitude to Associate Professor and advisor, Dr. Isra Sarntisart, and committee member, Professor Dr. Pirom Kamolratanakul for their guidance, valuable comments, advice and continuous encouragement in completion of this thesis. I am deeply indebted to Associate Professor and chairperson, Dr. Siripen Supakankunti and associate professor and committee member Dr. Pongsa Pornachaiwiseskul for their extensive support in this regard.

I am very much grateful to Programme Director Associate Professor Dr.Wattana Janjaroen including all members of Center for Health Economics for their continuous support and encouragement. I extend my special thanks to Mrs. Kingthong for her tireless support through out the year.

I would like to take this opportunity to thank Health Economist Mr. Subhash Pokhrel, whose continuous encouragement directed me to study Health Economics and do this research.

I am deeply grateful to Dr. Dirgha Singh Bam, Director of National Tuberculosis Center, Nepal /SAARC TB Center, and Mr. Tara Singh Bam, Planning Officer NTC, for their guidance and kind support during my fieldwork for this report. Special gratitude is also extended to Dr. P. Kumar, Deputy Director of SAARC, Dr. Takashi Yoshiyama, Chief advisor of CTB & LHP-JICA, Dr. Shanta B. Pande, Senoir Research Officer Nuffield Institute for Health/NTP Project, Dr. Puspa Malla, NTC, Dr. K. K. Jha, NTC, Dr. Bhawana Shrestha, Project Chief-GENETUP and Mr. Amir Khati, Chief of DPHO Kathmandu for their keen interest, active support and valuable suggestions.

It will be worth mentioning that, this study in Health Economics would not have been possible without the financial support from Research Training Grants of UNDP/World Bank/ WHO Special programme for Research and Training in Tropical Diseases (TDR). My sincere thanks and appreciation also goes to Mr. Staven Wayling, Manager-TDR for his kind co-operation.

Let me express my sincere gratitude to His Majesty's Government of Nepal, Ministry of Health for the opportunity to pursue my study in Health Economics.

I would like to express my sincere thanks to Dr. Kunwar, Director BPH, Dr. Gupta Bahadur Shreshtha, Coordinator HHCN, Mr Luke, Project Director FSB, Mr. Bhakta Bahadur K.C. MD Anam Nagar Poly Clinic, Dr. Khageshwor Gelal, Ramghat PHC, Mr. Laxman Aryal, Officer Ministry of Finance, Mr. J.P. Dahal, Mr. Badri Gyawali. Mr. Dhurba Khadka, Mr. Deepak Karki. Mr. Chiri Babu Maharjan, Mr. Anil Sharma, Mr. Nava Raj Subedi, Mr. Rajesh Shreshtha. Mr. Ram Bahadur Thapa, Mr. Bharat, and Mr Damodar Gautam for their unstinting support in providing the concerned information in this regard.

Last but not the least, I express my heartfelt thanks to Sociologist Mrs. Rita Pohkrel (Gnawali), my wife, for her wonderful support in data collection, morale support including technical backstopping in analysis of data for this report.

Devendra Prasad Gnawali May, 2002.

### **CONTENTS**

		Page
Abst	tract (Thai)	iv
Abst	tract (English)	V
Ackr	nowledgements	vi
Cont	tents	vii
Lists	s of Tables	xii
Lists	s of Figures	xiv
Abb	reviations	xv
CHA	APTERS	
I	Introduction	1
	1.1 Background	1
	1.2 Rational	5
	1.3 Research Question	6
	1.4 Research Objective	6
	1.5 Benefits of the Study	6
	1.6 Scope of the Study	6
II	Literature Review	7
	2.1 Public-Private Mix Models	7
	2.1.1 Public-Private Mix Project Running by Mahavir Hospital	7
	2.1.2 A variety of Public-Private Mix Delivery Models	7
	2.2 Theoretical Differences between For-Profit and	
	Not-For-Profit Providers	10
	2.3 Theoretical Approach	12
	2.3.1 Cost Classification	14
	2.3.2 Cost Allocation of Shared Inputs	15
	2.3.3 Measures of Effectiveness	16

# CONTENTS (Contd...)

		Page
CHA	APTERS	
III	Research Methodology	18
	3.1 Research Design.	18
	3.2 Operational definition	18
	3.3 Conceptual Framework	21
	3.4 Study Areas	23
	3.5 Study Population, Sampling and Inclusion Criteria	23
	3.6 Cost Calculation	24
	3.6.1 Cost of Donated drugs	25
	3.6.2 Imported Drugs/Goods	25
	3.6.3 Economic cost of Capital Items	26
	3.6.4 Effect of Tax	27
	3.6.5 External Factors Affecting Providers' Cost	28
	3.6.6 Providers' Future Cost of Treatment	28
	3.6.7 Necessary Conditions for Successful Treatment	29
	3.6.8 Division of Cost Centers	29
	3.7 Data collection and Analysis	30
	3.8 Effectiveness Measurement	34
	3.9 Cost-effectiveness Analysis	35
	3.10 Sensitivity Analysis	35
IV	Results and Analysis	36
	4.1 Providers' Cost Calculation	36
	4.1.1 Cost Calculation of Ramghat PHC	36
	4.1.2 Cost Calculation of Friends of Shanta Bhawan	39
	4.2.3 Cost Calculation of Helping Hands Clinic	44
	4.2.4 Cost Calculation of Anam Nagar Poly Clinic	47

## CONTENTS (Contd...)

	Page
4.2.5 Cost Calculation of Birendra Police Hospital	54
4.3. Material Cost Calculation	59
4.3.1 Allocation of Direct Cost	59
4.3.2 Allocation of Indirect Cost	59
4.3.3 Drug Cost Calculation	61
4.4 Full Providers' Costs for Various DOTS Centers	63
4.5 Effectiveness of Public and PPM DOTS Centers	64
4.5.1 Ramghat PHC	64
4.5.2 Friends of Shanta Bhawan	65
4.5.3 Helping Hands Clinic	67
4.5.4 Anam Nagar Poly Clinic	68
4.5.5 Birendra Police Hospital	70
4.6 Cost-effectiveness Analysis	72
4.7 Sensitivity Analysis	74
CHAPTER	
V Discussion and conclusion	76
5.1 Discussion	76
5.2 Conclusion	82
5.3 Policy Implication	82
5.4 Limitation of the Study	83
References	84

Page	
Appendices 88	
Appendix A1: Capital Cost Calculation of Ramghat PHC88	
Appendix A2: Capital Cost Calculation of FSB	
Appendix A3: Capital Cost Calculation of Helping Hands Clinic90	
Appendix A4: Capital Cost Calculation of Anam Nagar Poly Clinic91	
Appendix A5: Capital Cost Calculation of Birendra Police Hospital92	
Appendix B1: Material Cost of Ramghat PHC93	
Appendix B2: Material Cost of Friends of Shanta Bhawan94	
Appendix B3: Material Cost of Helping Hands Clinic95	
Appendix B4: Material Cost of Anam Nagar Poly Clinic96	
Appendix B5: Material Cost of Birendra Plice Hospital97	
Appendix B6: Calculation of Allocation Proportion for Material Cost98	
Appendix B7: Administration Related Indirect Cost	
Appendix B8: Building Related Indirect Cost	
Appendix C1: Storage and Transportation Cost of Drugs	
Appendix C2: Drug Cost- Ramghat PHC104	
Appendix C3: Drug Cost- Friends of Shanta Bhawan105	
Appendix C4: Drug Cost- Helping Hands Clinic	
Appendix C5: Drug Cost- Anam Nagar Poly Clinic	
Appendix C6: Drug Cost- Birendra Police Hospital	
Appendix C7: Drug cost for Failure, Died, Defaulter and Transfer out109	
Appendix D : Allocation Proportion of Ramghat PHC110	
Appendix E1: Allocation Proportion of FSB (Treatment Unit)111	
Appendix E2: Allocation Proportion of FSB (Laboratory Unit)112	
Appendix F1: Allocation Proportion of HHC (Treatment Unit)113	
Appendix F2: Allocation Proportion of HHC (Laboratory Unit)114	

	Page
Appendix F3: Allocation Proportion of HHC (Radiology Unit)	115
Appendix G1: Allocation Proportion of Anam Nagar (Treatment unit).	
Appendix G2: Allocation Proportion of Anam Nagar (LaboratoryUnit)	117
Appendix G3: Allocation Proportion of Anam Nagar (RadiologyUnit).	118
Appendix H: Health Service coverage Fact Sheet	119
Appendix I: Map of Kathmandu Metropolitan City	120
Appendix J: Nepal Social Indicators	121
Curriculum Vitae	122

### **List of Tables**

Table		Page
1.1	TB  Incidence Ratio in SEAR Countries	3
1.2	Health Outcomes of National Tuberculosis Programme in Nepal	3
2.1	Guidelines for Developing Countries	13
2.2	Cost Determinant Component	15
2.3	Examples of Cost–effectiveness Measures	17
3.1	Estimates of Tuberculosis Cases in Kathmandu Metropolitan City	23
3.2	Summary of Data Requirement and their Sources	31
3.3	Identification, Measurement and Valuation of Costs	31
3.4	Criteria for Allocation of Overhead Cost	31
4.1	Capital Cost of Ramghat PHC	38
4.2	Labor Cost of Ramghat PHC	41
4.3	Capital Cost Calculation of Friends of Shanta Bhawan	39
4.4	Labor Cost Calculation of Friends of Shanta Bhawan	43
4.5	Capital Cost Calculation of Helping Hands Clinic	45
4.6	Labor Cost Calculation of Helping Hands Clinic	48
4.7	Capital Cost Calculation of Anam Nagar Poly Clinic	50
4.8	Labor Cost Calculation of Anam Nagar Poly Clinic	53
4.9	Capital Cost Calculation of Birendra Police Hospital	57
4.10	Labor Cost Calculation : Birendra Police Hospital	58
4.11	Material Cost to Various DOTS Centers	60
4.12	Unit Cost of Drug with Transportation and Storage Cost	61
4.13	Drug Cost for Cured and Completed Cases	62
4.14	Drug Cost for Failure, Defaulted, Died and Transfer out Cases	62
4.15	Total Drug Cost Incurred by Cured/Complete, failure, defaulter	62
4.16	Full Providers' Costs of Various DOTS Centers	63
4.17	Full Providers' Cost of DOTS Centers, without opportunity Cost	63

# List of Tables (Contd...)

Table	Pa	ige
4.18	Case Finding and Treatment Outcomes of Ramghat PHC	.65
4.19	Smear Conversion of Smear-positive Cases, Ramghat PHC	.65
4.20	Case Finding and Treatment Outcomes of FSB	.67
4.21	Smear Conversion of Smear-positive Cases, FSB	.67
4.22	Case Finding and Treatment Outcomes of HCC	.68
4.23	Smear Conversion of Smear-positive Cases, HHC	.69
4.24	Case Finding and Treatment Outcomes of Anam Nagar Poly Clinic	.70
4.25	Smear Conversion of Smear-positive Cases, Anam Nagar Poly Clinic	70
4.26	Case Finding and Treatment Outcomes of BPH	.71
4.27	Smear Conversion of Smear-positive Cases BPH	.72
4.28	Cost-effectiveness Ratio of Public and Public-Private Mix DOTS	
	Center	.72
4.29	Cost-effectiveness Ratio of Public and PPM-DOT Centers, omitting	
	Opportunity Cost	73
4.30	Cost-effectiveness Ratio with Capital Cost Annualized at 3%	
	Discount Rate	74
4.31	Cost-effectiveness Ratio with Capital Cost Annualized at 10%	
	Discount Rate	.75
4.32	Cost-effectiveness Ratio with Capital Cost Annualized at Different	
	Discount Rates	75
5.1	Providers' Routine Service Cost (RSC) (Without Drug and Direct	
	Material Cost)	80

# List of Figures

Figure		Page
3.1	Conceptual Framework	22
3.2	Effect of Tax and subsidy on demand and supply of health care service	s27

#### **Abbreviations**

APCRC : Anam Nagar Poly Clinic and Research Center

ARTI : Annual Rate of Tuberculosis Infection

BPH : Birendra Police Hospital

CEA : Cost-effectiveness Analysis

DOTS : Direct Observed Treatment, Short course

DTLA : District Tuberculosis and Leprosy Assistant

FSB : Friends of Shanta Bhawan

FY : Fiscal Year

HHCN : Helping Hands Clinic, Nepal

MDR-TB : Multi-drug Resistant TB

NRs : Nepalese Rupees

NTC : National Tuberculosis Center

NTP : National Tuberculosis Programme

PHC : Primary Health Center

PPM : Public-Private Mix

PPs : Private Practitioners

RTLA : Regional Tuberculosis and Leprosy Assistant

TB : Tuberculosis

WHO : World Health Organization